サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777778

炭疽菌治療の世界市場

Anthrax Treatment

出版日
ページ情報
英文 373 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
炭疽菌治療の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 373 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

炭疽菌治療の世界市場は2030年までに6億1,330万米ドルに達する見込み

2024年に4億900万米ドルと推定される炭疽菌治療の世界市場は、2024～2030年の分析期間においてCAGR 7.0%で成長し、2030年には6億1,330万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗生物質薬剤クラス別は、CAGR 7.8%を記録し、分析期間終了時には3億8,120万米ドルに達すると予測されます。免疫グロブリン薬剤クラス別セグメントの成長率は、分析期間中CAGR 6.2%と推定されます。

米国市場は1億1,140万米ドルと推定、中国はCAGR 11.1％で成長予測

米国の炭疽菌治療市場は、2024年に1億1,140万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億2,910万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の炭疽菌治療市場- 主要動向と促進要因のまとめ

なぜ炭疽菌治療は世界保健上の優先事項なのか？

炭疽菌（Bacillus anthracis）によって引き起こされる重篤な感染症である炭疽病は、広範なアウトブレイクを引き起こす可能性と生物兵器としての使用により、依然として公衆衛生上の重大な懸念事項となっています。この病気は主に家畜に感染するが、感染した動物や汚染された畜産物に直接接触することで人にも感染します。皮膚型、消化器型、吸入型、注射型の炭疽の重症度は様々であるが、吸入型炭疽が最も致死的です。致死率や長期的な健康合併症を最小限に抑えるためには、効果的な治療が不可欠であり、しっかりとした医療介入の重要性が強調されています。バイオテロのリスクの高まりは、炭疽菌治療の解決策の必要性をさらに浮き彫りにしています。政府や保健機関は、医療対抗策の開発や備蓄を含む、備えのための取り組みに積極的に投資しています。啓発キャンペーンや教育プログラムも、早期発見と対応能力を向上させ、利用しやすく効果的な治療法の必要性を強調しています。これらの努力は、炭疽菌が重大な脅威であること、そしてその影響を緩和する上で治療が重要な役割を果たすことを世界的に認識させるものです。

どのような進歩が炭疽菌治療の選択肢を変えるのか？

抗菌薬、生物学的製剤、支持療法などの進歩により、炭疽菌治療の状況は大きく変化しています。シプロフロキサシン、ドキシサイクリン、アモキシシリンなどの抗生物質は、特に皮膚型や吸入型の疾患に対して、炭疽菌治療の要であり続けています。しかし、最近の技術革新は、使用可能な選択肢の幅を広げています。raxibacumabやobiltoxaximabのようなモノクローナル抗体は、炭疽毒素を標的とする救命治療薬として登場し、従来の抗生物質に耐えられない、あるいは反応しない患者に代替手段を提供しています。さらに、炭疽ワクチンの開発は、予防と早期治療に極めて重要な役割を果たしています。BioThrax（AVA）ワクチンのようなワクチンは、軍人や緊急対応要員を含むリスクのある人々への予防接種に不可欠です。有効性と安全性を向上させた次世代ワクチンの研究は引き続き進められており、炭疽菌への暴露に対する予防効果の向上が期待されています。さらに、ポリメラーゼ連鎖反応（PCR）検査や迅速抗原検出システムなどの診断技術の進歩により、早期診断とタイムリーな治療が容易になり、患者の転帰が改善され、死亡率が低下しています。

地域動向は炭疽菌治療市場をどのように形成しているか？

炭疽菌治療の需要は地域によって異なり、公衆衛生のインフラストラクチャー、疾病の流行、政府のイニシアチブの違いに影響されます。北米は、高度なヘルスケアシステム、バイオテロ対策への多額の投資、研究開発活動への強力な支援によって市場を独占しています。米国政府の戦略的国家備蓄プログラムは、炭疽ワクチン、抗生物質、モノクローナル抗体の需要を促進する上で重要な役割を果たしており、生物学的攻撃やアウトブレイクが発生した場合に備えています。欧州では、人獣共通感染症に対する意識の高まりと公衆衛生対策への投資の増加が、炭疽菌治療ソリューションの採用を促進しています。ドイツ、英国、フランスなどの国々では、包括的な疾病監視システムを確立し、炭疽菌発生の可能性に対処するための対策を備蓄しています。一方、アジア太平洋地域は農業基盤が大きく、人獣共通感染症が頻繁に発生するため、急成長を遂げています。中国やインドのような国々は、炭疽菌対策としてワクチン生産とヘルスケア・インフラに投資しています。ラテンアメリカやアフリカは、家畜の数が多くヘルスケアへのアクセスが限られている地域であるため、独自の課題もあるが、認知度やヘルスケアへの取り組みが改善されれば市場拡大のチャンスもあります。

炭疽菌治療市場の成長の原動力は？

炭疽菌治療市場の成長は、バイオテロ対策への政府投資の増加、治療オプションの進歩、人獣共通感染症に対する意識の高まりなど、いくつかの要因によって牽引されています。家畜の多い地域では炭疽菌の流行が拡大しており、発生を予防・治療するためのワクチンや抗生物質の需要が高まっています。さらに、モノクローナル抗体療法の導入により、特に吸入性炭疽のような重篤な症例に対する効果的な治療法が提供され、市場の成長をさらに後押ししています。疾病監視、早期診断、対策へのアクセスを改善するための公衆衛生上の取り組みも、市場の拡大に寄与しています。安全性プロファイルが改善され、投与が容易な次世代ワクチンの開発に注力することで、特に高リスク集団における予防接種率の格差に対処しています。特にアジア太平洋とアフリカでは、ヘルスケア・インフラと研究活動への地域的投資が市場をさらに強化しています。これらの要因を総合すると、世界の健康安全保障における炭疽菌治療の重要な役割と市場の力強い成長軌道が浮き彫りになります。

セグメント

薬剤クラス別（抗生物質薬剤クラス、免疫グロブリン薬剤クラス、その他薬剤クラス）、感染タイプ別（皮膚感染、その他感染タイプ）、流通チャネル別（病院薬局、小売薬局、その他流通チャネル）

調査対象企業の例

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • BlueWillow Biologics, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corporation
  • GSK Plc
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Planet Biotechnology, Inc.
  • Porton Biopharma Limited
  • Soligenix, Inc.

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29171

Global Anthrax Treatment Market to Reach US$613.3 Million by 2030

The global market for Anthrax Treatment estimated at US$409.0 Million in the year 2024, is expected to reach US$613.3 Million by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Antibiotics Drug Class, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$381.2 Million by the end of the analysis period. Growth in the Immunoglobulins Drug Class segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$111.4 Million While China is Forecast to Grow at 11.1% CAGR

The Anthrax Treatment market in the U.S. is estimated at US$111.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$129.1 Million by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Anthrax Treatment Market - Key Trends & Drivers Summarized

Why Is Anthrax Treatment a Global Health Priority?

Anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis, remains a critical public health concern due to its potential to cause widespread outbreaks and its use as a biological weapon. The disease primarily affects livestock but can be transmitted to humans through direct contact with infected animals or contaminated animal products. Cutaneous, gastrointestinal, inhalational, and injectional forms of anthrax pose varying degrees of severity, with inhalational anthrax being the most lethal. Effective treatment is essential to minimize fatalities and long-term health complications, underscoring the importance of robust medical interventions. The heightened risk of bioterrorism has further spotlighted the need for anthrax treatment solutions. Governments and health organizations are actively investing in preparedness initiatives, including the development and stockpiling of medical countermeasures. Awareness campaigns and educational programs have also improved early detection and response capabilities, emphasizing the need for accessible and effective treatment options. Together, these efforts reflect the global recognition of anthrax as a significant threat and the critical role of treatment in mitigating its impact.

What Advances Are Transforming Anthrax Treatment Options?

The anthrax treatment landscape has evolved significantly with advancements in antimicrobial therapies, biologics, and supportive care strategies. Antibiotics, such as ciprofloxacin, doxycycline, and amoxicillin, remain the cornerstone of anthrax treatment, particularly for cutaneous and inhalational forms of the disease. Recent innovations, however, have expanded the scope of available options. Monoclonal antibodies like raxibacumab and obiltoxaximab have emerged as life-saving treatments, targeting anthrax toxins and offering an alternative for patients who cannot tolerate or do not respond to conventional antibiotics. Additionally, the development of anthrax vaccines has played a pivotal role in prevention and early intervention. Vaccines such as the BioThrax (AVA) vaccine are critical in immunizing at-risk populations, including military personnel and first responders. Research into next-generation vaccines with improved efficacy and safety profiles continues to advance, promising enhanced protection against anthrax exposure. Furthermore, advancements in diagnostic technologies, such as polymerase chain reaction (PCR) tests and rapid antigen detection systems, have facilitated early diagnosis and timely treatment, improving patient outcomes and reducing mortality rates.

How Are Regional Trends Shaping the Anthrax Treatment Market?

The demand for anthrax treatment varies across regions, influenced by differences in public health infrastructure, disease prevalence, and government initiatives. North America dominates the market, driven by its advanced healthcare systems, significant investments in bioterrorism preparedness, and strong support for research and development activities. The U.S. government’s strategic national stockpile program has played a key role in driving demand for anthrax vaccines, antibiotics, and monoclonal antibodies, ensuring readiness in the event of a biological attack or outbreak. In Europe, growing awareness of zoonotic diseases and increasing investments in public health preparedness are driving the adoption of anthrax treatment solutions. Countries such as Germany, the UK, and France have established comprehensive disease surveillance systems and stockpiled countermeasures to address potential anthrax outbreaks. Meanwhile, the Asia-Pacific region is witnessing rapid growth due to its large agricultural base and frequent zoonotic disease outbreaks. Countries like China and India are investing in vaccine production and healthcare infrastructure to combat anthrax. Latin America and Africa, regions with high livestock populations and limited healthcare access, present unique challenges but also opportunities for market expansion as awareness and healthcare initiatives improve.

What Is Driving Growth in the Anthrax Treatment Market?

The growth in the anthrax treatment market is driven by several factors, including increasing government investments in bioterrorism preparedness, advancements in therapeutic options, and rising awareness of zoonotic diseases. The growing prevalence of anthrax in livestock-rich regions has heightened demand for vaccines and antibiotics to prevent and treat outbreaks. Additionally, the introduction of monoclonal antibody therapies has provided effective treatment alternatives for severe cases, particularly inhalational anthrax, further driving market growth. Public health initiatives to improve disease surveillance, early diagnosis, and access to countermeasures are also contributing to the market’s expansion. The focus on developing next-generation vaccines with improved safety profiles and ease of administration is addressing gaps in immunization coverage, particularly in high-risk populations. Regional investments in healthcare infrastructure and research activities, especially in Asia-Pacific and Africa, are further bolstering the market. Collectively, these factors underscore the critical role of anthrax treatment in global health security and the market’s strong growth trajectory.

SCOPE OF STUDY:

The report analyzes the Anthrax Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antibiotics Drug Class, Immunoglobulins Drug Class, Other Drug Classes); Infection Type (Cutaneous Infection, Other Infection Types); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbVacc, Inc.
  • Acurx Pharmaceuticals
  • BlueWillow Biologics, Inc.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • GC Biopharma Corporation
  • GSK Plc
  • Paratek Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Planet Biotechnology, Inc.
  • Porton Biopharma Limited
  • Soligenix, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Anthrax Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Threat of Bioterrorism and Biosecurity Concerns Propel Market Demand for Anthrax Treatments
    • Increasing Government Stockpiling of Emergency Antibiotics and Biologics Strengthens Business Case for Anthrax Therapeutics
    • Advancements in Rapid Diagnostic Technologies Spur Early Detection and Timely Treatment of Anthrax Infections
    • Surging Demand for Monoclonal Antibodies and Immunotherapies Strengthens Market Growth for Biologic Anthrax Countermeasures
    • Increasing Awareness and Training on Bioterrorism Preparedness Generates Demand for Anthrax Medical Countermeasures
    • Integration of AI and Big Data in Epidemiology Enhances Surveillance and Response Strategies for Anthrax Outbreaks
    • Global Health Security Initiatives and Pandemic Preparedness Programs Propel Market Investment in Anthrax Treatment Solutions
    • Growing Interest in Novel Small-Molecule Antibiotics Expands Treatment Options for Antibiotic-Resistant Anthrax Strains
    • Expansion of Biopharmaceutical Research Pipelines Spurs Innovation in Targeted Anthrax Therapies
    • Increasing Military and Homeland Security Funding for Biothreat Preparedness Sustains Growth in Anthrax Treatment Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Anthrax Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Anthrax Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antibiotics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunoglobulins Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Immunoglobulins Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cutaneous Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cutaneous Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Cutaneous Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Infection Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Infection Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Anthrax Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Anthrax Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Anthrax Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Anthrax Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Anthrax Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Anthrax Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Anthrax Treatment by Drug Class - Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Anthrax Treatment by Drug Class - Percentage Breakdown of Value Sales for Antibiotics Drug Class, Immunoglobulins Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Anthrax Treatment by Infection Type - Cutaneous Infection and Other Infection Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Anthrax Treatment by Infection Type - Percentage Breakdown of Value Sales for Cutaneous Infection and Other Infection Types for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Anthrax Treatment by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Anthrax Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION